Bolt Biotherapeutics, Inc. (BOLT)

Market Cap	11.23M
Revenue (ttm)	3.64M
Net Income (ttm)	-63.35M
Shares Out	38.34M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	135,042
Open	0.2895
Previous Close	0.3170
Day's Range	0.2895 - 0.3051
52-Week Range	0.3000 - 1.3350
Beta	0.96
Analysts	Hold
Price Target	1.00 (+241.3%)
Earnings Date	May 12, 2025

About BOLT

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company dBDC-3042, develops dan agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer; and BDC-4182, an next-generation boltbody technology platform that targets claudin 18.2, which is overexpressed in gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types. The company has ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 5, 2021
• Employees: 52
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLT
• Website: https://www.boltbio.com

Financial Performance

In 2024, Bolt Biotherapeutics's revenue was $7.69 million, a decrease of -2.36% compared to the previous year's $7.88 million. Losses were -$63.12 million, -8.79% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for BOLT stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 241.30% from the latest price.

Price Target

$1.0

(241.30% upside)

Analyst Consensus: Hold